Skip to content




Vancouver Nanomedicine Day 2021

September 16, 2021 



Thanks to all the presenters, sponsors and participants in Vancouver Nanomedicine Day 2021 for making it another memorable and informative experience.

Recordings of most sessions from the event are available below.

Welcome & Introduction to Nanomedicines

Urs Häfeli

University of British Columbia

Organizer, Vancouver Nanomedicine Day 2021

INVITED TALK: Nanomedicines for oral delivery of peptides ‐ what have we learned?

David Brayden

University College Dublin,Ireland

In vivo and phantom imaging of cyclotron produced 133La as a theranostic radionuclide for 225Ac and 135La

Bryce Nelson

University of Alberta

Comparison of various radioactive payloads for a human monoclonal antibody to glycoprotein 41 for elimination of HIV‐infected cells

Ekaterina Dadachova

University of Saskatchewan

Customizable multifunctional metal nanotexaphyrin as a radiotheranostics agent for cancer imaging and therapy

Miffy Cheng

University of Toronto

Smart nanomaterials: a multi‐pronged strategy towards targeting bacteria

Ruby Sullan

University of Toronto Scarborough

Sprayable nanoparticle network hydrogels for promoting intranasal drug delivery to the brain

Todd Hoare

McMaster University

Nano‐delivery of novel inhibitors of DNA repair for targeted chemo‐ and radio‐sensitization of solid tumors

Afsaneh Lavasanifar

University of Alberta

INVITED TALK: Magnetized nanocarriers targeting brain delivery after stroke

Anna Rosell

Vall d’Hebron Institute of Research, Barcelona, Spain

KEYNOTE: Nucleoside‐modified LNP mRNA therapeutics

Drew Weissman

University of Pennsylvania, PA, USA

MicroRNA‐145 delivery by targeted peptide micelles for atherosclerosis therapy

Deborah Chin

University of Southern California, CA, USA

Development and optimization of LNP‐based gene therapy approaches in the brain

Blair Leavitt

Centre for Molecular Medicine and Therapeutics, UBC



This world-class symposium, the seventh event of its kind, gathered renowned Canadian and international experts from across the nanomedicines field to:

  • highlight the discoveries and innovations in nanomedicines that are contributing to global progress in acute, chronic and orphan disease treatment and management;
  • present up-to-date diagnostic and therapeutic  nanomedicine approaches to addressing the challenges of COVID-19; and
  • facilitate discussion among nanomedicine researchers and innovators and UBC and NMIN clinician-scientists, basic researchers, trainees, and research partners.

Since 2014, Vancouver Nanomedicine Day has advanced nanomedicine research, knowledge mobilization and commercialization in Canada by sharing high-impact findings and facilitating interaction—among researchers, postdoctoral fellows, graduate students, and life science and startup biotechnology companies—to catalyze research collaboration.


Dr. Urs Häfeli, PhD, Professor of Pharmaceutical Sciences at the University of British Colombia


Nanomedicine is an interdisciplinary research area within nanotechnology that aims to develop medical technologies at the nanoscale, ranging from drug delivery carriers and imaging agents to nanomaterials and nanoelectronic biosensors.

A cluster of researchers at the University of British Columbia (UBC) has organized this event since 2014.



Virtual Vancouver Nanomedicine Day 2021 featured:

  • A keynote address by the physician-scientist best known for his contributions to RNA biology, enabling the development of effective mRNA vaccines: Dr. Drew Weissman (University of Pennsylvania)
  • Invited talks by internationally renowned experts, including Dr. David Brayden (University College Dublin, Ireland), and Dr. Anna Rosell (Vall d’Hebron Institute of Research, Barcelona, Spain)
  • Presentations by other leading experts, including: Frank Wuest (University of Alberta), Ekaterina Dadachova (University of Saskatchewan), Miffy Cheng (University of Toronto), Ruby Sullan (University of Toronto Scarborough), Todd Hoare (McMaster University), Afsaneh Lavasanifar (University of Alberta), Suzie Pun (University of Washington), Deborah Chin (University of Southern California) and Blair Leavitt (University of British Columbia)

NOTE that all times in the program are in Pacific Daylight Time (PDT).

Featured speakers

Nucleoside-modified LNP mRNA therapeutics

Drew Weissman, University of Pennsylvania (USA)

Nanomedicines for oral delivery of peptides – what have we learned?

David Brayden, University College Dublin (Ireland)

Magnetized nanocarriers targeting brain delivery after stroke

Anna Rosell, Vall d’Hebron Institute of Research (Spain)



Registration to Virtual Vancouver Nanomedicine Day 2021 is free.

However, your advance registration is required for planning purposes.

We look forward to including you on September 16, 2021!

There is no registration fee for this event, but registration is required.

Upon registering, you will be emailed a link to join the event.

Did you register for this event without ever receiving a participation link by email?

Please register by September 4, 2019





Jazz Pharmaceuticals is a global biopharmaceutical company dedicated to bringing life-changing medicines to people with limited or no options, so they can live their lives more fully.

NanoVation Therapeutics (NVT) is an early-stage gene therapy company focused on developing personalised therapeutics to treat age-related conditions using lipid nanoparticle and nucleic acid-based technologies. NVT develops next-generation platform technologies to enable efficient extrahepatic gene therapy and is available for partnering opportunities.

The NanoMedicines Innovation Network (NMIN) is a federally-funded national research network that brings investigators from universities across Canada together with industry and public sector partners to expand and improve Canada’s position as world leader in nanomedicines R&D.


Uniquely operated in British Columbia as an independent CRO, BRI focuses on pre-clinical and clinical programs supporting biotech and pharmaceutical companies. BRI has capabilities in LC/MS/MS and multiplex ELISA bioanalytical, in-vivo and in-vitro drug metabolism, pharmacokinetics and human tumor xenograft mouse models.

Malvern Panalytical provides analytical systems and solutions which enable complex biophysical profiles to be characterized. Our approach includes a range of orthogonal and complementary analytical techniques along with consultation and applications expertise.

PNI is a global leader in technology and solutions for developing RNA, DNA, CRISPR, small molecule drugs, COVID vaccines and therapeutics rapidly taking ideas to patients.

STEMCELL Technologies Inc. supports global life sciences research with more than 2,500 specialized tools and services. They provide high quality cell culture media, cell separation technologies, instruments, accessory products and scientific services that are used by scientists conducting stem cell biology, immunology, cancer, regenerative medicine, and cellular therapy research.


Acuitas is a private company based in Vancouver, British Columbia that is partnered with multiple pharmaceutical companies, biotechnology companies and academic institutes to advance nucleic acid therapeutics to the clinic and to the marketplace. We work with partners to develop new therapies to address unmet clinical needs based on our internationally recognized capabilities in delivery technology.

Evonik, a global development and solutions partner to the pharma industry for over 60 years, provides drug delivery technologies, excipients, API manufacturing, intermediates, amino acid derivatives, and advanced food ingredients. As a leading CDMO, services include formulation & process development, GMP manufacturing & aseptic filling of drug products.

PHARMA INVENTOR INC. is a Canadian Chemistry R&D services company based in Vancouver, BC. We are very proud to service the Life Science BC community since 2013 and be recognized by them for our expertise in Medicinal Chemistry, Custom Organic Synthesis and Process Research & Development. Our mission is to provide inventive, reliable, cost-effective & high-quality chemistry solutions to our clients’ discovery R&D programs.

Founded in 1946, the Faculty of Pharmaceutical Sciences at UBC enjoys an international reputation in pharmacy education, innovation in pharmacy practice, and research in the pharmaceutical sciences.

adMare BioInnovations is Canada’s Global Life Sciences Venture, building the Canadian life sciences industry from sea to sea. They partner with leading academic researchers and biotech companies to advance commercially promising therapeutic innovations to create new companies of scale; and offer specialized scientific and commercial expertise, infrastructure and capital to help existing companies scale up.

Genome BC is a non-profit research organization that leads genomics innovation on Canada’s West Coast and facilitates the adoption of genomics into society.